Latest News
CRU Global Network Expands Reach Across CEE and South-East Asian Regions
We are excited to share the latest milestone in the CRU Global Network’s journey of expansion and impact in clinical research. In a strategic move, CRU has significantly extended its presence through the establishment of new sites and offices in key locations within the Central and Eastern European (CEE) region, including Poland, the Czech Republic, Slovakia, Croatia, and Serbia.
Additionally, CRU has expanded its footprint in the vibrant South-East Asian region, with new offices now open in Singapore and Malaysia. This expansion reaffirms our commitment to bringing cutting-edge clinical research solutions to diverse and dynamic healthcare landscapes.
CRU GLOBAL Network extend its presence in:
Central and Eastern Europe (CEE)
- Poland
- Czech Republic
- Slovakia
- Croatia
- Serbia
South-East Asia
- Singapore
- Malaysia
This strategic move allows CRU to enhance its capabilities, collaborate with regional experts, and contribute to advancing healthcare research in these critical regions.
CRU Global Network remains dedicated to extending its impact globally and creating new opportunities for groundbreaking clinical research. Stay tuned for further updates, as more exciting news is set to unfold!
Find out more about CRU Global! Contact us today!
CRU Global Network Expands Presence in Hungary with Three Specialized Phase I Units
Exciting news for the CRU community! We are thrilled to announce that CRU Global Network is set to establish three new, highly specialized Phase I units in Hungary during Q1 2024. This expansion marks a significant stride in our commitment to advancing clinical research and bringing cutting-edge solutions to the forefront.
The upcoming Phase I units will focus on the following areas
Pulmonology and Pulmo-oncology – Addressing respiratory and pulmonary oncology challenges with dedicated expertise.
Neurology and Neurosurgery – Exploring innovative solutions in the realms of neurology and neurosurgery for improved patient outcomes.
General Oncology and Solid Tumors – A specialized unit dedicated to advancing research in general oncology, with a specific focus on solid tumors.
More exciting news is on the horizon! CRU remains at the forefront of global clinical research, and these new Phase I units in Hungary reinforce our commitment to expanding capabilities and driving progress in key therapeutic areas.
We look forward to sharing more details in the coming months. Learn more about CRU Global’s services! Contact us today!
CRU Hungary Excels in Early Phase Oncology Studies for Solid Tumors
As highlighted by industry sources, the competition for sites and resources in oncology research is intense, driven by the rapid growth of oncology drugs in development. CRU Hungary stands as a reliable solution to enrollment challenges, offering expertise and efficiency in the increasingly complex landscape of oncology trials.
In the dynamic landscape of early phase oncology studies focusing on solid tumors, efficiency plays a pivotal role at every stage of clinical trial development and implementation. CRU Hungary emerges as a leading force, presenting key advantages that set us apart within the field.
Our Key Advantages
High-Quality Data
Our commitment to excellence is reflected in the high quality of data we produce, acknowledged and accepted by regulatory bodies such as the FDA, EMA, and others.
Fast Recruitment
CRU Hungary boasts a continuously expanding and easily accessible patient pool across various indications, fueled by the high incidence of cancer indications within Europe and globally. Our proactive recruitment strategies address the challenges of enrolling in oncology trials.
Simple Regulatory Process
We navigate the regulatory landscape seamlessly through the EU Clinical Trials Information System (CTIS), streamlining the approval process for swift trial initiation.
Experienced, Highly Educated Staff
Our team is composed of experienced and highly educated staff, including Principal Investigators (PIs) with over 30 years of study experience in oncology research.
State-of-the-Art Infrastructure
CRU Hungary operates with cutting-edge infrastructure, featuring an in-house trial pharmacy, safety lab, and radiology services (CT, MRI, US, DXA) to support the diverse needs of early phase oncology studies.
Full Site and CRO Services
From initial medical writing to the comprehensive final report, CRU Hungary provides a complete spectrum of Site and Contract Research Organization (CRO) services, ensuring seamless coordination throughout the trial lifecycle.
CRU is a good solution for your enrollment challenges!
Contact CRU Hungary today to explore how we can enhance and expedite your early phase oncology studies for solid tumors.
CRU Hungary Ltd Leads the Way in Early Phase Clinical Trials for Patients with Hepatic or Renal Impairment
In the realm of early phase clinical trials for patients with hepatic or renal impairment, CRU Hungary Ltd stands out as a trailblazer, showcasing unparalleled expertise within Europe.
Efficiency takes center stage throughout the entire spectrum of clinical trial development and execution. CRU Hungary Ltd, with its extensive experience, has become a frontrunner in ensuring the swift and effective progress of early phase clinical trials.
Our Key Advantages
High-Quality Data
Our commitment to excellence is evident in the consistently high quality of data we generate. Our data sets are accepted by the FDA, EMA, and all regulatory bodies.
Fast Recruitment
CRU Hungary Ltd boasts continuously increasing and readily accessible patient pools across various indications. This, coupled with our proactive recruitment strategies, ensures swift and efficient enrollment, expediting the trial timeline.
Simple Regulatory Process
Navigating the regulatory landscape is made seamless through our utilization of the EU Clinical Trials Information System (CTIS). This simplified regulatory process streamlines approvals, allowing for a quicker initiation of trials.
Experienced, Highly Educated Staff
The backbone of our success lies in our dedicated and knowledgeable team. With a wealth of experience and a commitment to ongoing education, our staff ensures the highest standards of expertise in the field.
State-of-the-Art Infrastructure
CRU Hungary Ltd operates with cutting-edge infrastructure, providing the technological backbone necessary for the successful execution of early phase clinical trials. Our facilities are equipped to meet the most rigorous standards of modern research.
Full Site and CRO Services
From initial medical writing to the comprehensive final report, CRU Hungary Ltd offers a complete spectrum of site and Contract Research Organization (CRO) services. Our integrated approach ensures seamless coordination throughout the trial lifecycle.
Learn more about CRU Hungary’s comprehensive Site and CRO services! Contact us today!
Mandatory use of CTIS from 31 January 2023 for all new clinical trial applications
On 31 January 2023, the use of the Clinical Trials Information System (CTIS) will become mandatory for new clinical trial applications and will serve as the single-entry point for submission by sponsors and for regulatory assessment. This follows one year of transition, during which sponsors could choose whether to submit a new clinical trial application in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022.
CRU Hungary performs all new study submissions according to the CTIS. CRU’s Regulatory team is familiar with the CTIS after many successfull submisisons within this new system.
